{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:41:30Z","timestamp":1794624090237,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41582-025-01123-5","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T17:58:46Z","timestamp":1753120726000},"page":"490-498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-5838","authenticated-orcid":false,"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"1123_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"E Nichols","year":"2022","unstructured":"Nichols, E. et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public Health"},{"key":"1123_CR2","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s Disease Facts and Figures (Alzheimer\u2019s Association, 2023)."},{"key":"1123_CR3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","volume":"80","author":"LE Hebert","year":"2013","unstructured":"Hebert, L. E. et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778\u20131783 (2013).","journal-title":"Neurology"},{"key":"1123_CR4","first-page":"889","volume":"77","author":"E Jutkowitz","year":"2020","unstructured":"Jutkowitz, E. et al. Societal and family lifetime cost of dementia: implications for policy. JAMA Neurol. 77, 889\u2013896 (2020).","journal-title":"JAMA Neurol."},{"key":"1123_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"1123_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"1123_CR7","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"1123_CR8","first-page":"563","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson, O. et al. Blood biomarkers for Alzheimer\u2019s disease. Nat. Rev. Neurol. 17, 563\u2013581 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1123_CR9","unstructured":"FDA. FDA clears first blood test used in diagnosing Alzheimer\u2019s disease. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease (2025)."},{"key":"1123_CR10","unstructured":"FDA. Early Alzheimer\u2019s disease: developing drugs for treatment. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/early-alzheimers-disease-developing-drugs-treatment (2024)."},{"key":"1123_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"1123_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s43587-023-00410-4","volume":"3","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. & Aisen, P. S. Detection and treatment of Alzheimer\u2019s disease in its preclinical stage. Nat. Aging 3, 520\u2013531 (2023).","journal-title":"Nat. Aging"},{"key":"1123_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40263-023-01021-8","volume":"37","author":"S Leisher","year":"2023","unstructured":"Leisher, S. et al. Amyloid-lowering monoclonal antibodies for the treatment of early Alzheimer\u2019s disease. CNS Drugs 37, 671\u2013677 (2023).","journal-title":"CNS Drugs"},{"key":"1123_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2023.11703","volume":"330","author":"GD Rabinovici","year":"2023","unstructured":"Rabinovici, G. D. & La Joie, R. Amyloid-targeting monoclonal antibodies for Alzheimer disease. JAMA 330, 507\u2013509 (2023).","journal-title":"JAMA"},{"key":"1123_CR15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling, R. A. et al. Trial of solanezumab in preclinical Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1096\u20131107 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1123_CR16","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","volume":"69","author":"S Ostrowitzki","year":"2012","unstructured":"Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198\u2013207 (2012).","journal-title":"Arch. Neurol."},{"key":"1123_CR17","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman, R. J. et al. Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N. Engl. J. Med. 389, 1862\u20131876 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1123_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S1474-4422(25)00024-9","volume":"24","author":"RJ Bateman","year":"2025","unstructured":"Bateman, R. J. et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer\u2019s disease: an open-label extension of the phase 2\/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial. Lancet Neurol. 24, 316\u2013330 (2025).","journal-title":"Lancet Neurol."},{"key":"1123_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537, 50\u201356 (2016).","journal-title":"Nature"},{"key":"1123_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1123_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1123_CR22","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun, M. A. et al. Donanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 384, 1691\u20131704 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1123_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512\u2013527 (2023).","journal-title":"JAMA"},{"key":"1123_CR24","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1123_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici, G. D. et al. Donanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 12, 100150 (2025).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1123_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi, M. et al. Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review. JAMA Neurol. 79, 291\u2013304 (2022).","journal-title":"JAMA Neurol."},{"key":"1123_CR27","unstructured":"Sperling, R. A. Lecanemab for the treatment of early Alzheimer\u2019s disease: the extension of efficacy results from clarity AD. In The 16th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference (CTAD, 2023)."},{"key":"1123_CR28","unstructured":"Johnson, K. Biomarker assessments from clarity AD: downstream implications of targeting protofibrils and tau as a predictive biomarker. In The 16th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference (CTAD, 2023)."},{"key":"1123_CR29","unstructured":"Mintun, M. A. Predicting efficacy in donanemab-treated participants. In The 16th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference (CTAD, 2023)."},{"key":"1123_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/alz.070865","volume":"19","author":"MAM Pugh","year":"2023","unstructured":"Pugh, M. A. M. TRAILBLAZER-ALZ 3 \u2014 a deeper dive into time-to-event trials. Alzheimers Dement. 19, e070865 (2023).","journal-title":"Alzheimers Dement."},{"key":"1123_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimers Dement."},{"key":"1123_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/alz.089308","volume":"20","author":"BA Willis","year":"2025","unstructured":"Willis, B. A. et al. Model\u2010based assessment of lecanemab maintenance dosing regimen shows continued suppression of amyloid plaque, disease progression. Alzheimers Dement. 20, e089308 (2025).","journal-title":"Alzheimers Dement."},{"key":"1123_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman, R. J. et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 13, 8\u201319 (2017).","journal-title":"Alzheimers Dement."},{"key":"1123_CR34","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2261509","volume":"15","author":"HP Grimm","year":"2023","unstructured":"Grimm, H. P. et al. Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. mAbs 15, 2261509 (2023).","journal-title":"mAbs"},{"key":"1123_CR35","unstructured":"Kulic, L. Trontenimab. In The 17th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference (CTAD, 2024)."},{"key":"1123_CR36","unstructured":"Phase Ib\/IIa Brainshuttle AD study of trontinemab. In AD\/PD 2025 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (2025)."},{"key":"1123_CR37","unstructured":"Jin, Y. Remternetug: preliminary clinical results. In AD\/PD 2023 International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (2023)."},{"key":"1123_CR38","unstructured":"Alexander, R. Post-FDA approval studies of donanemab. In Alzheimer\u2019s Association International Conference (AAIC) 2024 (AICC, 2024)."},{"key":"1123_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082852","volume":"19","author":"BA Willis","year":"2023","unstructured":"Willis, B. A., Penner, N., Rawal, S., Aluri, J. & Reyderman, L. Subcutaneous (SC) lecanemab is predicted to achieve comparable efficacy and improved safety compared to lecanemab IV in early Alzheimer\u2019s disease (AD). Alzheimers Dement. 19, e082852 (2023).","journal-title":"Alzheimers Dement."},{"key":"1123_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/alz.14167","volume":"20","author":"PS Aisen","year":"2024","unstructured":"Aisen, P. S. et al. Shifting the focus: amyloid reduction as a surrogate endpoint in Alzheimer\u2019s disease. Alzheimers Dement. 20, 1\u201315 (2024).","journal-title":"Alzheimers Dement."},{"key":"1123_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup. Alzheimers Dement. 7, 367\u2013385 (2011).","journal-title":"Alzheimers Dement."},{"key":"1123_CR42","first-page":"1722","volume":"18","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapies. Alzheimers Dement. 18, 1722\u20131732 (2022).","journal-title":"Alzheimers Dement."},{"key":"1123_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fneur.2013.00205","volume":"4","author":"PA Yates","year":"2014","unstructured":"Yates, P. A. et al. Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations. Front. Neurol. 4, 205 (2014).","journal-title":"Front. Neurol."},{"key":"1123_CR44","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos, J. et al. Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy. J. Prev. Alzheimers Dis. 9, 211\u2013220 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"1123_CR45","unstructured":"Sims, J. Modified titration of donanemab demonstrated reduction of ARIA-E in early symptomatic Alzheimer\u2019s disease patients in phase 3b study. In The 17th Clinical Trials on Alzheimer\u2019s Disease (CTAD) Conference (CTAD, 2024)."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01123-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01123-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:58:39Z","timestamp":1757264319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01123-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01123-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"3 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.S.R. is employed by the University of Southern California and the Alzheimer\u2019s Therapeutics Research Institute (ATRI) and has received grants or contracts from Eisai and Eli Lilly, which were paid to his institution. He has received consulting fees from AC Immune and Ionis. He has participated on a data safety monitoring board or an advisory board for Alzheon, Alnylam, Biohaven, Embic, Prescient Imaging, Positrigo and Recall Therapeutics. P.S.A. has research grants from the National Institutes of Health, Eli Lilly and Eisai, and consults with Merck, Roche, BMS, Genentech, Abbvie, Biogen, ImmunoBrain Checkpoint, Arrowhead, AltPep and Neurimmune.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}